DREAMM20

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Near Add Your Location

Sorting 2 by

START Midwest
Midwest
Grand Rapids, MI
  • Accepting patients
Sarah Cannon Research Institute
TriStar Centennial Medical Center
Nashville, TN
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.